Atomo Diagnostics (ASX:AT1)
We spoke to John Kelly, CEO of Atomo Diagnostics (ASX:AT1), about progress the company is making towards profitability and how aspects of the Atomo pipeline, such as the syphylis diagnostic, are making this company world-class.
Disclosure: Atomo Diagnostics is a research client of Pitt Street Research and our directors own AT1 shares.
Looking for the Best ASX Life Sciences stocks to invest in right now?
